Registered title, quoted from ClinicalTrials.gov
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07537946, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Hepatocellular carcinoma confirmed by imaging and/or histology according to institutional diagnostic standards
Inclusion criterion 2
Child-Pugh class A or stable Child-Pugh B7
Inclusion criterion 7
Prior PD-1, PD-L1, CTLA-4, anti-VEGF monoclonal antibody, tyrosine kinase inhibitor, or other systemic antitumor therapy for advanced HCC
Exclusion criterion 5
ECOG performance status 0 to 1
Inclusion criterion 6
At least 1 measurable lesion according to RECIST version 1.1
Inclusion criterion 4
Pregnancy or breastfeeding
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07537946, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18 to 75 years
- Hepatocellular carcinoma confirmed by imaging and/or histology according to institutional diagnostic standards
- Advanced or unresectable disease with extrahepatic metastases meeting protocol-defined oligo-extrahepatic metastatic disease criteria: 1 to 5 extrahepatic metastatic lesions and no more than 2 involved extrahepatic organs
- At least 1 measurable lesion according to RECIST version 1.1
- No prior systemic therapy for advanced or metastatic hepatocellular carcinoma
- ECOG performance status 0 to 1
- Child-Pugh class A or stable Child-Pugh B7
- Adequate hematologic, hepatic, renal, and coagulation function according to protocol
- Baseline center multidisciplinary team assessment indicating potential feasibility for complete consolidative intent if disease control is achieved after induction
- Written informed consent and willingness to comply with treatment, follow-up, and protocol-required assessments
Exclusion Criteria:
- More than 5 extrahepatic metastatic lesions or more than 2 involved extrahepatic organs
- Diffuse peritoneal seeding, leptomeningeal disease, or uncontrolled brain metastases
- Main portal vein trunk invasion, extensive inferior vena cava or right atrial tumor thrombus, or disease considered unlikely to become fully consolidable after induction
- Diffuse intrahepatic disease or liver tumor burden considered unlikely to be controllable with protocol-specified local treatment
- Prior PD-1, PD-L1, CTLA-4, anti-VEGF monoclonal antibody, tyrosine kinase inhibitor, or other systemic antitumor therapy for advanced HCC
- Active autoimmune disease requiring systemic immunosuppression
- Active severe infection, including uncontrolled bacterial or fungal infection, active tuberculosis, or uncontrolled hepatitis B without appropriate antiviral therapy
- Gastrointestinal bleeding within the previous 6 months, or untreated or uncontrolled high-risk gastroesophageal varices
- Uncontrolled hypertension, recent major thrombotic event, myocardial infarction, unstable angina, or stroke
- Active interstitial lung disease or noninfectious pneumonitis requiring systemic treatment
- Severe proteinuria or renal dysfunction considered unsuitable for lenvatinib treatment
- Pregnancy or breastfeeding
- Any condition that, in the investigator's judgment, would make participation unsafe or compromise protocol compliance
Quoted from ClinicalTrials.gov, NCT07537946, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07537946, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.